Results 31 to 40 of about 336,282 (259)

Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome

Frontiers in Physiology, 2019
Background/Aims: Gut microbiota has been reported to correlate with a higher mortality and worse prognosis of cardiovascular diseases. Trimethylamine N-oxide (TMAO) is a gut microbiota-dependent metabolite of specific dietary nutrients, which is linked ...
Xueling Li, Jin Geng, Jinxuan Zhao, Qianqian Ni, Chenze Zhao, Yaru Zheng, Xiaomin Chen, Lihong Wang   +7 more
doaj   +1 more source

Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention

Frontiers in Pharmacology, 2023
Cardiac fibrosis plays an indispensable role in cardiac tissue homeostasis and repair after myocardial infarction (MI). The cardiac fibroblast-to-myofibroblast differentiation and extracellular matrix collagen deposition are the hallmarks of cardiac ...
Xiaoying Yin, Xiaoying Yin, Xiaoying Yin, Xiaoying Yin, Xinxin Yin, Xinxin Yin, Xinxin Yin, Xinxin Yin, Xin Pan, Xin Pan, Xin Pan, Xin Pan, Jingyu Zhang, Jingyu Zhang, Jingyu Zhang, Jingyu Zhang, Xinhui Fan, Xinhui Fan, Xinhui Fan, Xinhui Fan, Jiaxin Li, Jiaxin Li, Jiaxin Li, Jiaxin Li, Xiaoxuan Zhai, Xiaoxuan Zhai, Xiaoxuan Zhai, Xiaoxuan Zhai, Lijun Jiang, Lijun Jiang, Lijun Jiang, Lijun Jiang, Panpan Hao, Jiali Wang, Jiali Wang, Jiali Wang, Jiali Wang, Yuguo Chen, Yuguo Chen, Yuguo Chen, Yuguo Chen   +40 more
doaj   +1 more source

Time spent with cats is never wasted: Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring animal model of the human disease [PDF]

, 2018
BackgroundIn humans, acromegaly due to a pituitary somatotrophic adenoma is a recognized cause of increased left ventricular (LV) mass. Acromegalic cardiomyopathy is incompletely understood, and represents a major cause of morbidity and mortality.
A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Mestron, A Piovesan, AC Dirtu, AM Pereira, B Posch, BJ Maron, BPP Meij, BR Bond, C Paige, C-Y Liu, CJL Little, CR Lamb, David B. Church, David J. Connolly, DJ Connolly, F Fracassi, G Jacobs, G Lombardi, G Lombardi, J Dal, J Gilbert, JA Myers, JK Sangster, JM Fletcher, JR Payne, JT Lie, Kieran Borgeat, LJ Wilkie, Lois Wilkie, M Galderisi, M Lesser, M Maxie Grant, M Nishiki, M Rosca, M-LL Jaffrain-Rea, MD Kittleson, ME Peterson, ME Peterson, NJ Pereira, Norelene Harrington, NS Moise, NS Moise, O Kershaw, OM Dekkers, P Menaut, PR Fox, PR Fox, PR Fox, PR Fox, PR Fox, R Baldelli, R Gostelow, R Pivonello, RC Weichselbaum, S Brown, S Fazio, S Fazio, S Fazio, S Fieffe, S Murarka, S Niessen, SJM Niessen, SJM Niessen, SJM Niessen, SK Liu, SK Liu, Stijn J. M. Niessen, SV Keyte, T Wagner, T. Rosol, Vincenzo Lionetti, Virginia Luis Fuentes, WL McGuffin   +80 more
core   +2 more sources

Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2 [PDF]

, 2009
Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in the therapeutic benefit for ACE2 overexpression in the heart.
Allen, James M., Baker, Andrew H., Chamberlain, Jeffrey S., Craig, Margaret Anne, Dominiczak, Anna F., Gilday, Kirsten, Graham, Delyth, Gregorevic, Paul, Masson, Rachel, McBride, Martin, Napoli, Claudio, Nicklin, Stuart A., Smith, Godfrey   +12 more
core   +1 more source

Vascular peroxidase 1 is a novel regulator of cardiac fibrosis after myocardial infarction

Redox Biology, 2019
Cardiac fibrosis is the most important mechanism contributing to cardiac remodeling after myocardial infarction (MI). VPO1 is a heme enzyme that uses hydrogen peroxide (H2O2) to produce hypochlorous acid (HOCl).
Zhaoya Liu, Qian Xu, Qixin Yang, Jing Cao, Cong Wu, Huihui Peng, Xinyi Zhang, Jia Chen, Guangjie Cheng, Yueheng Wu, Ruizheng Shi, Guogang Zhang   +11 more
doaj   +1 more source

Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

Medicina, 2023
Background and Objectives: Advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) can be a major predictor of cardiovascular disease (CVD) events and cardiac complications. However, the clinical significance of cardiac symptoms
Min-Kyu Kang, Min-Cheol Kim
doaj   +1 more source

Therapeutic Potential of Polyphenols in Cardiac Fibrosis

Frontiers in Pharmacology, 2018
Cardiac fibrosis, in response to injury and stress, is central to a broad constellation of cardiovascular diseases. Fibrosis decreases myocardial wall compliance due to extracellular matrix (ECM) accumulation, leading to impaired systolic and diastolic ...
Ning Zhang, Ning Zhang, Ning Zhang, Wen-Ying Wei, Wen-Ying Wei, Wen-Ying Wei, Ling-Li Li, Ling-Li Li, Ling-Li Li, Can Hu, Can Hu, Can Hu, Qi-Zhu Tang, Qi-Zhu Tang, Qi-Zhu Tang   +14 more
doaj   +1 more source

Sphingosine 1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis? [PDF]

, 2017
Sphingosine 1-phosphate (S1P) is a bioactive lipid that is characterized by a peculiar mechanism of action. In fact, S1P, which is produced inside the cell, can act as an intracellular mediator, whereas after its export outside the cell, it can act as ...
Frati, Alessia, Meacci, Elisabetta, Monaco, Lucia, Pierucci, Federica, Vestri, Ambra   +4 more
core   +2 more sources

Rescue of Pressure Overload-Induced Heart Failure by Estrogen Therapy. [PDF]

, 2016
BackgroundEstrogen pretreatment has been shown to attenuate the development of heart hypertrophy, but it is not known whether estrogen could also rescue heart failure (HF).
Bopassa, Jean C, Centala, Alexander, Eghbali, Mansoureh, Iorga, Andrea, Li, Jingyuan, Nadadur, Rangarajan D, Ren, Shuxun, Saito, Tomoaki, Sharma, Salil, Stefani, Enrico, Toro, Ligia, Umar, Soban, Wang, Yibin   +12 more
core   +1 more source

Selecting patients with nonischemic dilated cardiomyopathy for ICDs [PDF]

, 2017
No abstract ...
Cleland, John G.F., Halliday, Brian P., Prasad, Sanjay K.   +2 more
core   +1 more source